Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 28, 2023

Brigatinib vs Alectinib for ALK-Positive NSCLC After Disease Progression on Crizotinib

Journal of Thoracic Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Thoracic Oncology
Brigatinib Versus Alectinib in ALK-positive Non-small Cell Lung Cancer After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial
J Thorac Oncol 2023 Aug 11;[EPub Ahead of Print], J Chih-Hsin Yang, G Liu, S Lu, J He, M Burotto, MJ Ahn, DW Kim, X Liu, Y Zhao, S Vincent, J Yin, X Ma, HM Lin, S Popat

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading